CGRP mAb Subcutaneous denied for missing prior authorization by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for cgrp mab subcutaneous are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Requires Prior Authorization for CGRP Monoclonal Antibodies

UnitedHealthcare requires prior authorization (PA) for subcutaneous CGRP monoclonal antibodies because they are specialty drugs with significant cost and clinical-use criteria that UHC wants to verify before approving coverage. A denial coded as "prior authorization required" means either (a) no PA request was submitted before dispensing, (b) a PA was submitted but did not include sufficient information to approve, or (c) the PA was denied on clinical grounds and the denial code was communicated as a PA failure. The root cause matters because the right remedy differs for each scenario.

## Why This Denial Is Appealable

Even when the denial is framed as a procedural PA failure, you have appeal rights. Under ACA §2719 and ERISA §503, any adverse benefit determination — including a PA denial — must go through a full-and-fair review. If the underlying PA was denied on clinical grounds, that clinical decision is subject to internal appeal and independent external review, with the external-review window generally running 4 months from the final internal denial. Expedited review is available when the clinical situation is urgent.

## The Appeal Process

1. Determine the exact reason for the PA failure: missing submission, insufficient documentation, or clinical denial. 2. If the PA was never submitted, contact the prescriber's office immediately — submitting PA with complete documentation is faster than a formal appeal in many cases. 3. If the PA was denied clinically, file a formal written internal appeal. Request UHC's clinical criteria for this drug class and address each criterion in the appeal letter. 4. Request a prescriber peer-to-peer review — UHC must offer this option, and it often resolves PA denials before a formal appeal is needed. 5. If internal appeal is upheld, escalate to external review.

## Documentation to Gather

• Prior authorization submission record: A copy of the original PA request and any supporting materials already submitted.
• Clinical criteria checklist: UHC's published PA criteria for this drug class, obtained from UHC's provider portal or Coverage Determination Guideline.
• Diagnosis and severity documentation: Specialist notes confirming diagnosis, migraine frequency, and functional impairment.
• Stepwise treatment history: Documented list of prior preventive therapies tried, with dates, outcomes, and reasons for discontinuation.
• Prescriber medical-necessity letter: Tailored to address every PA criterion point-by-point.

## Criteria-Mapping Structure

Obtain the current PA criteria from UHC's coverage policy and compare them to the FDA-approved prescribing label. Build a response that addresses each criterion in sequence. Cite specific chart entries — visit dates, documented headache diaries, pharmacy records — for each requirement. The closer your documentation mirrors UHC's own criteria language, the higher the likelihood of approval.